Acella Pharmaceuticals has recalled its thyroid medication for the third time in a year over potency issues.
Tim HayesContributing Editor, Healthcare Packaging Healthcare Packaging
May 14th, 2021
A recent
WebMDarticle discussed a nationwide thyroid drug recall linked to incorrect information on the label. The drug in question is Acella Pharmaceuticals’ NP Thyroid medication intended to treat hypothyroidism. During routine testing, the affected lots were found to contain less than 90% of the two ingredients listed on the label: liothyronine and levothyroxine.
At least 43 adverse events have been reported in relation to the drug, which could be linked to the recall. This is the third recall related to this particular drug’s potency in the past year. Back in November, the potency was too low, and last May it was overly potent.
Cough Syrup Market Size Is Projected To Reach USD 6,108 25 Million By 2027 sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
Some NP Thyroid Lots Recalled Due to Reduced Potency medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Thyroid Medicine Gets Third Major Recall Over Lack of onenewspage.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onenewspage.com Daily Mail and Mail on Sunday newspapers.